Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer (Q24186509)

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

A Gynecologic Oncology Group Study of serum CA-125 levels in patients with stage III optimally debulked ovarian cancer treated with intraperitoneal compared to intravenous chemotherapy: an analysis of patients enrolled in GOG 172.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

A comparison of intravenous versus intraperitoneal chemotherapy for the initial treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

A comparative study of intraperitoneal carboplatin versus intravenous carboplatin with intravenous cyclophosphamide in both arms as initial chemotherapy for stage III ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

Importance of delivered cycles and nomogram for intraperitoneal chemotherapy in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

Intraperitoneal cisplatin versus no further treatment: 8-year results of EORTC 55875, a randomized phase III study in ovarian cancer patients with a pathologically complete remission after platinum-based intravenous chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

Phase ii/iii study of intraperitoneal chemotherapy after neoadjuvant chemotherapy for ovarian cancer: ncic ctg ov.21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

Can carboplatin replace cisplatin for intraperitoneal use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

Three ongoing intraperitoneal chemotherapy trials in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

Complications associated with intraperitoneal chemotherapy catheters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

Intraperitoneal chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: a randomized trial of the Gruppo Oncologico Nord-Ovest

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

7 January 2021

Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

7 January 2021

Clinical pharmacology of intraperitoneal cisplatin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

7 January 2021

Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

7 January 2021

Intraperitoneal cisplatin-based chemotherapy vs. intravenous cisplatin-based chemotherapy for stage III optimally cytoreduced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

7 January 2021

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

7 January 2021

A Randomized Phase II/III Trial of 3 Weekly Intraperitoneal versus Intravenous Carboplatin in Combination with Intravenous Weekly Dose-dense Paclitaxel for Newly Diagnosed Ovarian, Fallopian Tube and Primary Peritoneal Cancer

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

7 January 2021

Intraperitoneal cisplatin with systemic thiosulfate protection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005340.PUB4

7 January 2021